Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Gathering information about cognitive function over time in postmenopausal women with breast cancer may help doctors learn about the long-term effects of aromatase inhibitor therapy and plan the best treatment.

PURPOSE: This clinical trial is studying cognitive function in older postmenopausal women with stage I, stage II, or stage III breast cancer receiving hormone therapy and in healthy volunteers.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: City of Hope Medical Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Anastrozole; Letrozole

Criteria

DISEASE CHARACTERISTICS:

• Meets 1 of the following criteria:

• Patient diagnosed with breast cancer

• Stage I-III disease

• Estrogen receptor- and/or progesterone receptor-positive

• Planning to start treatment with anastrozole or letrozole

• Age-matched healthy volunteer (control)

• No history of breast cancer

• Not receiving adjuvant aromatase inhibitor therapy

PATIENT CHARACTERISTICS:

• Postmenopausal

• Able to converse, write, and read English

• No claustrophobia (patients participating in the PET scan correlative study)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior hormonal therapy, including estrogen replacement therapy

• No previous treatment with CNS radiation